Otsuka (OTCMKTS:OTSKY) Releases FY 2026 Earnings Guidance

Otsuka (OTCMKTS:OTSKY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.639-1.639 for the period, compared to the consensus estimate of 0.000. The company issued revenue guidance of $16.4 billion-$16.4 billion, compared to the consensus revenue estimate of $16.4 billion.

Otsuka Stock Performance

Shares of Otsuka stock opened at $34.36 on Wednesday. The company’s 50 day moving average price is $29.77 and its 200-day moving average price is $28.20. Otsuka has a 52-week low of $21.64 and a 52-week high of $34.93.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Zacks Research cut shares of Otsuka from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. UBS Group raised Otsuka to a “hold” rating in a report on Tuesday, January 27th. Finally, Morgan Stanley upgraded shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.